Home > Healthcare > Pharmaceuticals > Finished Drug Form > Scopolamine Market
Scopolamine Market Size
- Report ID: GMI9743
- Published Date: Jun 2024
- Report Format: PDF
Scopolamine Market Size
Scopolamine Market size was valued at around USD 419 million in 2023 and is estimated to grow at 5.3% CAGR from 2024 to 2032. Scopolamine, also known as hyoscine, is a tropane alkaloid derived from plants of the nightshade family (Solanaceae), such as henbane (Hyoscyamus Niger). It is primarily known for its anticholinergic properties, meaning it inhibits the action of the neurotransmitter acetylcholine in the central and peripheral nervous systems.
The rise in chronic diseases such as cardiovascular diseases, diabetes, and cancer has led to an increase in surgical interventions, many of which require effective management of preoperative and postoperative nausea and vomiting. According to the American Cancer Society, around 20 million new cancer cases were diagnosed globally in 2022, with 9.7 million deaths resulting from the disease. Projections indicate that by 2050, the number of cancer cases is expected to rise to 35 million, driven solely by anticipated population growth.
| Report Attribute | Details |
|---|---|
| Base Year: | 2023 |
| Scopolamine Market Size in 2023: | USD 419 Million |
| Forecast Period: | 2024 - 2032 |
| Forecast Period 2024 - 2032 CAGR: | 5.3% |
| 2032 Value Projection: | USD 663.1 Million |
| Historical Data for: | 2021 - 2023 |
| No. of Pages: | 192 |
| Tables, Charts & Figures: | 280 |
| Segments covered: | Dosage Form, Application, Route of Administration, Distribution Channel, and Region |
| Growth Drivers: |
|
| Pitfalls & Challenges: |
|
This surge in chronic diseases is stimulated by aging population, sedentary lifestyles, and unhealthy diets, resulting in a higher number of patients needing surgical procedures. Scopolamine is widely used to prevent and treat postoperative nausea and vomiting (PONV), a common complication following surgery. Thus, as hospitals and surgical centers focus on improving patient outcomes and comfort, the demand for scopolamine to alleviate nausea and vomiting will significantly increase.
Furthermore, increased global travel and a health-conscious population have driven greater recognition and diagnosis of motion sickness and related nausea. With more individuals experiencing motion sickness due to travel, scopolamine has emerged as an effective treatment. Improved awareness and diagnostics have further identified those can benefit from scopolamine, expanding its use beyond motion sickness to other nausea-related conditions such as chemotherapy-induced nausea, widening its market reach.
Frequently Asked Questions (FAQ) :
Scopolamine Market Scope
